Aurobindo Pharma reports profit growth on strong domestic demand for HIV drugs
Aurobindo Pharma reported a 7.6 percent rise in profit today behind strong demand for HIV drugs. Revenue grew over 8 percent despite North American price pressure.
Insights:
Aurobindo Pharma Limited announced its third quarter financial results on Monday, reporting a 7.6% rise in consolidated profit after tax to 9.1 billion Indian rupees. The company also saw its consolidated revenue increase by 8.4% to 86.46 billion rupees. These figures reflect a period of growth driven by specific domestic segments, even as the firm navigates a complex international pricing environment.
The quarterly performance was supported by steady domestic demand within India 
IN, with a significant contribution from anti-retroviral therapies. The sales of these anti-retroviral drugs provided a necessary boost to the company's top-line results, helping to offset various external pressures. This domestic strength is a notable factor for the company as it maintains its position among prominent Indian generic drugmakers.
IN, with a significant contribution from anti-retroviral therapies. The sales of these anti-retroviral drugs provided a necessary boost to the company's top-line results, helping to offset various external pressures. This domestic strength is a notable factor for the company as it maintains its position among prominent Indian generic drugmakers.
